Obesity is a major growing health concern around the world. In most markets, a
person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms
per square meter (kg/m2), calculated by dividing body mass in kilograms by
height in meters squared. With the global prevalence continuing to rise, the
disease has placed significant burden on healthcare expenditure, as it is also
a major risk factor for cardiovascular diseases, diabetes and cancer.

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification
to improve weight loss in order to significantly reduce obesity-associated
health risks in obese patients. However, the use of currently available
anti-obesity drugs is largely limited by poor long-term safety and a modest
weight loss effect. Despite substantial clinical and regulatory challenges, the
early-stage obesity pipeline remains robust, containing a high level of
first-in-class innovation that has the potential to be translated into
effective and safe weight loss treatments.

Historically, the obesity market has suffered from long-term safety concerns
and modest efficacy with current treatments, both of which contribute to the
low prescription rate and limited widespread use.
- What are the main safety concerns that lead to significant challenges in
gaining drug approval in obesity?
- Why is sustainable weight loss difficult to achieve, and what is the
implication for future drug development?
Analysis reveals a high level of innovation and diversity in the pipeline, with
75 first-in-class programs identified to act on 60 unique molecular targets.
- What is the dominant target family across these first-in-class pipeline
products?
- How well do they align with the underlying signaling pathways governing the
central and peripheral regulation of food intake, and energy expenditure?
Some first-in-class targets are deemed more likely to be developed into
marketable treatments than others, having demonstrated substantial body weight
reduction in Preclinical studies and addressing multiple mechanisms
underpinning the development of obesity.
- What is the scientific rationale behind these targets? How are they likely to
surpass existing treatment?
- Apart from body weight change, what other parameters are commonly used to
measure the effect of investigational therapies?
Deals involving first-in-class obesity products are more likely to be made in
earlier stages of development than non-first-in-class deals, supported by
industry-wide analysis.
- What is the dominant molecular target in the obesity deals landscape?
- What are the promising first-in-class products still available for future
licensing?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering
disease pathogenesis, diagnosis, prognosis, and the available treatment options
and their limitations in terms of safety and efficacy.
- Visualize the composition of the obesity market to highlight the current
unmet needs in order to gain a competitive understanding of the key
opportunities.
- Analyze the obesity pipeline and stratify by stage of development, molecule
type, and molecular target; the diversity of molecular targets in the pipeline
is extremely encouraging as obesity is characterized by the complex interplay
between central and peripheral mechanisms.
- Assess the therapeutic potential of first-in-class targets using a
proprietary matrix that assesses and ranks first-in-class products according to
clinical potential.
- Target the most promising and innovative obesity products for early-stage
investment by analyzing trends in licensing and co-development deals and
accessing a curated list of first-in-class therapies potentially open to
deal-making opportunities.

Market Reports Center is an e-commerce platform obliging the
needs of knowledge workers, experts, professionals who are subject to market
research information for their work, or to make strategic business decisions.
Market Reports Center’s team consistently works to update and extend our
existing repository of market research reports by partnering with new
publishers and adding their studies to our website.